CN102309674B - Use of traditional Chinese drug composition in preparing drug for treating atrioventricular block - Google Patents
Use of traditional Chinese drug composition in preparing drug for treating atrioventricular block Download PDFInfo
- Publication number
- CN102309674B CN102309674B CN201110274565.5A CN201110274565A CN102309674B CN 102309674 B CN102309674 B CN 102309674B CN 201110274565 A CN201110274565 A CN 201110274565A CN 102309674 B CN102309674 B CN 102309674B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a use of a traditional Chinese drug composition in preparing a drug for treating atrioventricular block. The traditional Chinese drug composition comprises the following traditional Chinese drugs: ginseng, creeping liriope, dogwood, dan-shen root, fried spine date seed, Chinese taxillus herb, red peony, ground beetle, Chinese nardostachys root and rhizome, and the like. The results of clinical experiments show that: the traditional Chinese drug composition provides a significant clinical effect for treatment of the atrioventricular block.
Description
The present patent application is dividing an application of No. 200810054809.7 patent application.The original application applying date is 2008.4.18 day; Application number is: 200810054809.7; Denomination of invention is: the application of a kind of Chinese medicine composition in preparation treatment bradyarrhythmia medicine.
Technical field
The present invention relates to the application of a kind of Chinese medicine composition in preparation treatment slow arrhythmia medicine, belong to Chinese herbal medicine application.
Background technology
Arrhythmia (cardiac arrhythmia) refers to that any one such as the rhythm of the heart origin position, cardiac frequency and the rhythm and pace of moving things and conduction of impulse are abnormal.The implication of the word such as " cardiac arrhythmia " or " arrhythmia " biases toward and represents the not normal of the rhythm and pace of moving things, and arrhythmia not only comprises the rhythm and pace of moving things but also comprise the abnormal of frequency, and more definite and appropriate, arrhythmia has a strong impact on the blood-pumping function of heart, in time treatment.
Arrhythmia can be divided into sinus arrhythmia, atrial arrhythmia, atrioventricular junction arrhythmia, ventricular arrhythmia and heart block according to arrhythmia happening part; And according to the speed of the arrhythmia rhythm of the heart, arrhythmia can be divided into Quick-type and slow arrhythmia.[the 2nd edition P172-212 in Ye Rengao internal medicine People's Health Publisher October in 1984].
Bradyarrhythmia is impaired sinus node failure, the pacing function obstacle of causing of sinus-node self-activity being caused by many reasons, or because causing conduction function, sinuatrial node, atrium, atrioventricular node and atrioventricular bundle pathological changes reduce, make due to the crackled with excitement of sinuatrial node can not pass down as scheduled, its Clinical symptoms be the rhythm of the heart slowly and hemodynamics change.Slow arrhythmia comprises conduction block in sinus bradycardia, sinoatrial block, sinus standstill, sick sinus syndrome, room, atrioventricular block and intraventricular block etc.Clinically often show as that Consciousness Disturbances Following is crossed in dizziness, blindness, cardiopalmus, one, the symptom such as faint, severe patient produces cardiogenic syncope, even can cause death; Clinical pulse condition shows as slow pulse more and ties generation.Wherein heart rate slowly and rule take sinus bradycardia, 2: 1 or 3: 1 or dissociation or sino atrial block, the atrioventricular junction rhythm of the heart as common.Slow and irregular person be take atrial fibrillation, sinus bradycardia companion arrhythmia, sinus rhythm and is merged irregular antrum or Atrioventricular Conduction as common.
Patent ZL02146572.X discloses a kind of pharmaceutical composition for the treatment of Coronary heart disease ventricular early throb and preparation method thereof, and present patent application quotes in full the content that patent ZL02146572.X records.The application of unexposed this pharmaceutical composition of this patent in preparation treatment slow arrhythmia medicine, and application only limits to the treatment of Coronary heart disease ventricular early throb, and the present invention has done further research on the basis of this patented technology.Confirm, Chinese medicine composition of the present invention has significant clinical efficacy to slow arrhythmia.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine composition and restrain the application in not normal medicine at the slow sexual type of preparation treatment.
The invention provides a kind of Chinese medicine composition and restrain the application in not normal medicine at the slow sexual type of preparation treatment, it is characterized in that, this Chinese medicine composition is made by the crude drug of following weight portion:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part.
The weight ratio of Chinese medicine composition Raw medicine of the present invention is preferably:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
The weight ratio of Chinese medicine composition Raw medicine of the present invention is also preferably:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
The weight ratio of Chinese medicine composition Raw medicine of the present invention is also preferably:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis.
In application of the present invention, the active component of this Chinese medicine composition is made by the following step:
A) people participates in 70% alcohol reflux three times, and merge extractive liquid, filters, concentrated, dries the fine powder being ground into;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters concentrated extractum;
C) fine powder that Eupolyph aga sinesis Walker is broken into;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, merge extractive liquid,, concentrated extractum.
E) by step b) and d) gained extractum merge, add step c) fine drug powder of gained, dry, be ground into fine powder, add a) gained fine drug powder of step, mix and obtain this Chinese medicine composition active component.
In application of the present invention, described Chinese medicine composition is capsule, tablet, electuary, a kind of in powder or oral liquid formulations for above-mentioned dosage form can be realized, need add the acceptable adjuvant of pharmacy, for example: filler when these dosage forms of preparation, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic etc., filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc., disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc., lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc., suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc., binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc., sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc., correctives comprises: sweeting agent and various essence, antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, acetic acid chloroethene is fixed, Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods.
In the present invention's application, described slow arrhythmia is preferably sinus bradycardia.
In the present invention's application, described slow arrhythmia is also preferably sinoatrial block.
In the present invention's application, described slow arrhythmia is also preferably sick sinus syndrome.
In the present invention's application, described slow arrhythmia is also preferably conduction block in room, atrioventricular block or intraventricular block.。
The consumption of Chinese medicine composition of the present invention, by active component crude drug gross weight, is 7-28 gram/day, can take every day once, preferably divides and takes for 2-4 time.
The specific embodiment
Following embodiment is for illustrating the preparation of Chinese medicine composition of the present invention, but it can not form any restriction to scope of the present invention.
Embodiment 1
For the ease of the application of this traditional Chinese medicine composition for treating slow arrhythmia, this Chinese medicine composition is prepared as to capsule
Prescription:
Radix Ginseng 89g 112g Radix Ophiopogonis Fructus Corni 224g Radix Salviae Miltiorrhizae 224g
Semen Ziziphi Spinosae (parched) 186g Herba Taxilli 186g Radix Paeoniae Rubra 89g Eupolyphaga Seu Steleophaga 75g
Radix Et Rhizoma Nardostachyos 89g Rhizoma Coptidis 45g Fructus Schisandrae Sphenantherae 67g Os Draconis 149g
Preparation method:
A) in above-mentioned prescription, 70% alcohol reflux three times for Radix Ginseng, 3 hours for the first time, each 2 hours later, merge extractive liquid,, filtered, and reclaims ethanol, concentrated, dries, and is ground into fine powder, standby;
B) in above-mentioned prescription, 70% alcohol reflux three times for Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos, merge extractive liquid,, filters, and reclaims ethanol, and the concentrated extractum that to obtain is standby;
C) in above-mentioned prescription, Eupolyph aga sinesis Walker is broken into fine powder, standby;
D) in above-mentioned prescription, Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water secondary, and merge extractive liquid, filters, and the extracting solution of filtrate and Fructus Schisandrae Sphenantherae etc. merges, and concentrates to obtain extractum, standby;
E) by step b) and d) gained extractum merge, add step c) fine drug powder of gained dries, and is ground into fine powder, adds a) gained fine drug powder of step, mixes, and packs 1000 capsules into.
Usage and consumption: oral.One time 2～4,3 times on the one.
Test example
For illustrating the activity of traditional Chinese medicine composition for treating slow arrhythmia of the present invention, use the capsule (hereinafter referred to as medicine of the present invention) making by above-described embodiment 1 method to carry out following clinical trial.
1 data and method
1.1 physical data all cases are all selected from Hebei Yi Ling Patients during Hospital Ward, amount to 74 examples, are divided at random treatment group and matched group, every group of 37 examples.Treatment group man 20 examples, female's 17 examples, mean age (55.23 ± 7.05) year; Average course of disease (7.6 ± 2.5) year; Types of arrhythmia: sinus bradycardia 12 examples, sinus arrest 4 examples, sick sinus syndrome 8 examples, II degree sinoatrial block 8 examples, II Aminophyline 5 examples; Protopathy: coronary heart disease 20 examples, viral myocarditis 8 examples, cardiomyopathy 4 examples, hypertensive heart disease 5 examples.Matched group man 21 examples, female's 16 examples; Year mean age (56.02 ± 8.11); Average course of disease (8.2 ± 2.3) year; Types of arrhythmia: sinus bradycardia 12 examples, sinus arrest 5 examples, sick sinus syndrome 7 examples, II degree sinoatrial block 9 examples, II Aminophyline 4 examples; Protopathy: coronary heart disease 19 examples, viral myocarditis 9 examples, cardiomyopathy 5 examples, hypertensive heart disease 4 examples.Process there was no significant difference (P > 0.05) learning by statistics aspect sex, age, the course of disease and ill-distribution, there is comparability for two groups.
1.2 case selection inclusion criterias: 40～70 years old (1) age, male or female; (2) with reference to < < cardiovascular diseases's Differential Diagnosis > > [Marvin's pearl. cardiovascular diseases's Differential Diagnosis (M). Nanjing: Jiangsu science tech publishing house, 1992:97～98] diagnostic method, electrocardiographic diagnosis: heart rate≤50 time/min, total heart rate≤75000 time of 24h ambulatory electrocardiogram (Holter), average heart rate≤50 time/min.Exclusion standard: (1) merges the primary diseases such as cardiovascular, liver, kidney and hemopoietic system; (2) allergic constitution, has allergies person to multi-medicament; (3) trimester of pregnancy or women breast-feeding their children.In addition, if appearring in selected patient, the one of following situations also stops this research: (1) serious adverse reaction person occurs; (2) there is serious organ failure person.
1.3 Therapeutic Method matched groups adopt atropine treatment, 0.3g/ time, 3 times/day.Treatment group adds and uses Drug therapy of the present invention on matched group medication basis, and 4 tablets/time, 3 times/day.Be 4 weeks the course for the treatment of.Other arrhythmia Chinese and western drugses of simultaneously stopping using.
1.4 observation index: observe 24 hourly average hearts rate before and after treatment, the soonest and the slowest heart rate number of times.
1.5 curative effect determinate standards: take Shanghai " therapy of combining Chinese and Western medicine coronary heart diseases and angina pectoris and arrhythmia " forum < < angina pectoris in 1997 and arrhythmia evaluation criteria > > is criterion of therapeutical effect.Recovery from illness: clinical symptom disappearance, electrocardiogram is roughly normal, Holter (dynamic ecg) show heart rate (sinus rhythm) through be everlasting 60 times/more than min; Effective: clinical cardinal symptom disappears, and electrocardiogram obviously improves, show before 24h average heart rate (sinus rhythm) is than treatment >=10 times/min of Holter; Effective: clinical cardinal symptom partly disappears, electrocardiogram is treated front improvement, and Holter shows before 24h average heart rate (sinus rhythm) is than treatment increases >=5 times/min; Invalid: clinical symptoms and electrocardiogram are without improvement, and Holter shows that 24h average heart rate (sinus rhythm) is without increasing or increase by 5 times/min of <.
1.6 statistical procedures adopt SPSS13.0 statistical software to carry out date processing, and measurement data is with mean ± standard deviation
represent, adopt t check, enumeration data adopts x
2check.
2 results
By statistics, treatment group patient's total effective rate is apparently higher than matched group (P < 0.05) for 2.1 Clinical efficacy comparisons.The results are shown in Table 1.
Table 1 liang group patient clinical curative effect comparison (%)
Note: * and # be x relatively
2=4.57, P < 0.05.
Before and after 2.2 treatments Holter situations by statistics, treatment group 24 hourly average hearts rate, the soonest and the slowest heart rate number of times all apparently higher than matched group (P < 0.05).The results are shown in Table 2.
The comparison of Holter situation before and after table 2 liang group patient treatment
Note: * and # be P < 0.05 relatively; * and ## be P < 0.05 relatively;
with ◆ compare P < 0.05.
3 conclusions
This research is on the basis of doctor trained in Western medicine conventional therapy, add Drug therapy of the present invention, improving clinical efficacy, increase by 24 hourly average hearts rate, the soonest and the aspect such as the slowest heart rate number of times be all better than simple western medical treatment, fully proved invention medicine has significant clinical efficacy to slow arrhythmia.
Claims (6)
1. the application of Chinese medicine composition in preparation treatment atrioventricular block medicine, is characterized in that, this Chinese medicine composition is made by the crude drug of following weight portion:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part.
2. application as claimed in claim 1, is characterized in that, this Chinese medicine composition is made by the crude drug of following weight portion:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
3. application as claimed in claim 1, is characterized in that, this Chinese medicine composition is made by the crude drug of following weight portion:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
4. application as claimed in claim 1, is characterized in that, this Chinese medicine composition is made by the crude drug of following weight portion:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis.
5. the application as described in claim 1-4, is characterized in that, the active component of this Chinese medicine composition is made by the following step:
A) people participates in 70% alcohol reflux three times, and merge extractive liquid, filters, concentrated, dries the fine powder being ground into;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters concentrated extractum;
C) fine powder that Eupolyph aga sinesis Walker is broken into;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, merge extractive liquid,, concentrated extractum;
E) by step b) and d) gained extractum merge, add step c) fine drug powder of gained, dry, be ground into fine powder, add a) gained fine drug powder of step, mix and obtain this Chinese medicine composition active component.
6. the application as described in any one in claim 1-4, is characterized in that, the preparation formulation of described Chinese medicine composition is a kind of in capsule, tablet, electuary, powder or oral liquid formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110274565.5A CN102309674B (en) | 2008-04-18 | 2008-04-18 | Use of traditional Chinese drug composition in preparing drug for treating atrioventricular block |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110274565.5A CN102309674B (en) | 2008-04-18 | 2008-04-18 | Use of traditional Chinese drug composition in preparing drug for treating atrioventricular block |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100548097A Division CN101559162B (en) | 2008-04-18 | 2008-04-18 | Application of traditional Chinese medicine composition in preparing medicament for curing slow arrhythmia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102309674A CN102309674A (en) | 2012-01-11 |
| CN102309674B true CN102309674B (en) | 2014-01-29 |
Family
ID=45423482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110274565.5A Active CN102309674B (en) | 2008-04-18 | 2008-04-18 | Use of traditional Chinese drug composition in preparing drug for treating atrioventricular block |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102309674B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403148A (en) * | 2002-10-24 | 2003-03-19 | 河北以岭医药研究院有限公司 | Medicines composition for treating coronary heart disease ventricular premature beat and its prepn |
-
2008
- 2008-04-18 CN CN201110274565.5A patent/CN102309674B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403148A (en) * | 2002-10-24 | 2003-03-19 | 河北以岭医药研究院有限公司 | Medicines composition for treating coronary heart disease ventricular premature beat and its prepn |
Non-Patent Citations (2)
| Title |
|---|
| 参松养心胶囊治疗心率慢时室性早搏的疗效观察;张玉芝;《中国实用医药》;20071231;第2卷(第36期);160 * |
| 张玉芝.参松养心胶囊治疗心率慢时室性早搏的疗效观察.《中国实用医药》.2007,第2卷(第36期),160. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102309674A (en) | 2012-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101607006B (en) | Application of Chinese medicinal composition in preparing medicament for treating hypertension | |
| CN102908513B (en) | Application of traditional Chinese medicine composition in medicine for treating arrhythmia | |
| CN102309675B (en) | Application of Chinese medicine composition in preparing medicines for treating sick sinus syndrome | |
| CN101698050B (en) | Application of traditional Chinese medicine composite in preparing medicine treating paroxysmal atrial fibrillation | |
| CN101167838B (en) | Traditional Chinese medicinal preparation for treating coronary heart disease and angina pectoris and its preparing process | |
| CN101632783B (en) | Application of Chinese medicinal composition in preparing medicament for treating cor pulmonale | |
| CN101342207B (en) | Chinese medicinal composition for treating coronary disease, stenocardia, arrhythmia, hyperlipemia and preparation method thereof | |
| CN102309674B (en) | Use of traditional Chinese drug composition in preparing drug for treating atrioventricular block | |
| CN102579804B (en) | Chinese medicine for treating stenocardia | |
| CN101559162B (en) | Application of traditional Chinese medicine composition in preparing medicament for curing slow arrhythmia | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN102210807B (en) | Application of traditional Chinese medicine composition in preparation of medicaments for treating angina pectoris | |
| CN101313990B (en) | Application of a Chinese medicinal composition in preparing medicament for treating neurosis | |
| CN101590178B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating refractory premature beat of elderly patient | |
| CN103623207A (en) | Applications of traditional Chinese medicine composition in preparation of medicines used for treating chronic heart failure together with arrhythmia | |
| CN101683458B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for treating vertigo | |
| CN102895514B (en) | Application of Chinese medicine composition in preparing medicines for treating pulmonary heart disease | |
| CN101658568B (en) | Application of Chinese medicinal composition in preparing medicament for treating pulmonary heart disease | |
| CN101411814B (en) | Use of Chinese medicinal composition in preparing medicament for treating intraventricular block | |
| CN101744905B (en) | Applications of Chinese medicinal composition in preparation of medicament for treating pulmonary heart disease | |
| CN107753738A (en) | A kind of application of Chinese medicine composition in the medicine for preparing treatment pulmonary hypertension | |
| CN103961429B (en) | Traditional Chinese medicine composition having effects of moving qi and invigorating blood circulation and preparation method thereof | |
| CN105168653A (en) | Traditional Chinese medicine composition used for treating coronary heart disease | |
| CN105267470B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating coronary heart disease | |
| CN103007200B (en) | Medicament for treating coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |